Literature DB >> 2687331

Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model.

M Basta1, P Kirshbom, M M Frank, L F Fries.   

Abstract

Studies were performed in in vitro and in vivo models to assess the effect of intravenous immunoglobulin (IVIG) on the development of acute complement-mediated tissue damage. IVIG significantly increased the duration of survival and frequently prevented the death of guinea pigs injected with anti-Forssman antiserum to cause lethal Forssman shock; no control animal treated with albumin and/or maltose vehicle survived. The most pronounced effect was achieve by delivering IVIG as one slow injection at 1,800 mg/kg 3 h before Forssman shock was elicited. Infusion of guinea pig IgG at the same dosage was similarly protective. A strong positive correlation was found between IgG plasma levels and survival time in guinea pigs treated with graded doses of IVIG. Therapy itself did not affect C3 and C4 levels nor the capacity to activate these components. In vitro studies showed almost complete inhibition of C3 uptake onto IgG-sensitized erythrocytes using serum from an IVIG-treated animal. We suggest that supraphysiologic levels of IVIG act in part by preventing active C3 fragments from binding to target cells. Infusion of high dose IVIG may be a rational approach to modulating acute, complement-dependent tissue damage in a variety of diseases in man.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2687331      PMCID: PMC304080          DOI: 10.1172/JCI114387

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  A study of the cellular distribution of Forssman antigen in various species.

Authors:  E H LEDUC; N TANAKA
Journal:  J Immunol       Date:  1956-09       Impact factor: 5.422

2.  Heterophile antibodies and tissue injury. 3. A role for platelets in the development of lethal vascular injury during Forssman shock in guinea pigs.

Authors:  C C Tsai; N S Taichman; W H Pulver; E Schönbaum
Journal:  Am J Pathol       Date:  1973-08       Impact factor: 4.307

3.  The relative efficacies of 7S and 19S Forssman antibody in producing lesions in the guinea pig.

Authors:  N Bauman; W J Elliott
Journal:  Proc Soc Exp Biol Med       Date:  1972-02

4.  The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.

Authors:  K J Gadd; K B Reid
Journal:  Biochem J       Date:  1981-05-01       Impact factor: 3.857

5.  High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.

Authors:  P Imbach; S Barandun; V d'Apuzzo; C Baumgartner; A Hirt; A Morell; E Rossi; M Schöni; M Vest; H P Wagner
Journal:  Lancet       Date:  1981-06-06       Impact factor: 79.321

6.  Classical complement pathway activation by antipneumococcal antibodies leads to covalent binding of C3b to antibody molecules.

Authors:  E J Brown; M Berger; K A Joiner; M M Frank
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

7.  Interaction of C3 and C3b with immunoglobulin G.

Authors:  J Kulics; E Rajnavölgyi; G Füst; J Gergely
Journal:  Mol Immunol       Date:  1983-08       Impact factor: 4.407

8.  Generation of low m.w., C3-bearing immunoglobulin in human serum.

Authors:  R J Jacobs; M Reichlin
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

9.  Large scale isolation of functionally active components of the human complement system.

Authors:  C H Hammer; G H Wirtz; L Renfer; H D Gresham; B F Tack
Journal:  J Biol Chem       Date:  1981-04-25       Impact factor: 5.157

10.  Immunopharmacological approach to Forssman shock.

Authors:  H Nagai; Y Kurimoto; A Koda
Journal:  Microbiol Immunol       Date:  1980       Impact factor: 1.955

View more
  34 in total

1.  Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification.

Authors:  E Jelezarova; A Vogt; H U Lutz
Journal:  Biochem J       Date:  2000-07-01       Impact factor: 3.857

2.  The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids.

Authors:  W M Vuist; I N Van Schaik; M Van Lint; A Brand
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

Review 3.  Anti-inflammatory effect of intravenous immunoglobulin mediated through modulation of complement activation.

Authors:  Hans U Lutz; Peter J Späth
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

4.  Age-related changes in the hepatic microcirculation in mice.

Authors:  Yoshiya Ito; Karen K Sørensen; Nancy W Bethea; Dmitri Svistounov; Margaret K McCuskey; Bård H Smedsrød; Robert S McCuskey
Journal:  Exp Gerontol       Date:  2007-04-29       Impact factor: 4.032

Review 5.  Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases.

Authors:  S V Kaveri; G Dietrich; V Hurez; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

6.  GM-CSF and IL-4 are not involved in IVIG-mediated amelioration of ITP in mice: a role for IL-11 cannot be ruled out.

Authors:  B J B Lewis; D Leontyev; A Neschadim; M Blacquiere; D R Branch
Journal:  Clin Exp Immunol       Date:  2018-09       Impact factor: 4.330

7.  High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.

Authors:  M Basta; M C Dalakas
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

Review 8.  Intravenous immune globulin in recurrent abortion.

Authors:  O Heine; G Mueller-Eckhardt
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

9.  Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation.

Authors:  J C Magee; B H Collins; R C Harland; B J Lindman; R R Bollinger; M M Frank; J L Platt
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

10.  Anti-idiotypic activity against anti-myeloperoxidase antibodies in pooled human immunoglobulin.

Authors:  A A Pall; M Varagunam; D Adu; N Smith; N T Richards; C M Taylor; J Michael
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.